The U.S. DoA testing market is primarily driven by the stringent laws and regulations, government initiatives, and increasing awareness against drug abuse and development of advanced drug test equipment.

Request to get a Free Sample Copy of this Research Report at https://www.vynzresearch.com/healthcare/us-drug-of-abuse-testing-market/request-sample

The DOA tests make use of human samples such as urine, saliva, hair, blood, breath, and others. Urine is majorly used for drug abuse testing since it contains parent drugs or metabolites in them, that is tested for the presence of major illicit drugs. The urine samples lead the global DOA testing market based on size. Some of the other sample type used includes tissue and sweat.

The stringent laws and regulations, government initiatives to curb drug abuse, and increasing awareness against drug abuse and development of advanced drug test equipment are the primary growth drivers for the U.S. DoA testing industry. The substance misuse and its addiction of opioids such as morphine and heroin have been a serious concern for the U.S. government as it affects the socio-economic welfare and public healthcare.

Explore Full Research Report Description at https://www.vynzresearch.com/healthcare/us-drug-of-abuse-testing-market

Some of the key players operating in the U.S. Drug of Abuse Testing market are Siemens AG, Danaher Corporation, Merck KGaA, Laboratory Corporation of America Holdings, Express Diagnostics Int’l, Inc., Quest Diagnostics Inc., Waters Corporation, Abbott Laboratories, Psychemedics Corporation, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., and F. Hoffmann-La Roche AG.

Source: VynZ Research